Steven R. Loranger's Insider Trades & SAST Disclosures
Steven R. Loranger's most recent trade in Edwards Lifesciences Corp was a trade of 3,528 Common Stock done . Disclosure was reported to the exchange on May 9, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Steven R. Loranger.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 3,528 | 63,900 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,154 | 65,054 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.32 per share. | 14 Feb 2025 | 5,739 | 66,111 (0%) | 0% | 45.3 | 260,073 | Common Stock |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 5,739 | 0 | - | - | Director Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Sale of securities on an exchange or to another person at price $ 76.42 per share. | 14 Feb 2025 | 5,739 | 60,372 (0%) | 0% | 76.4 | 438,576 | Common Stock |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 3,055 | 59,373 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 999 | 60,372 (0%) | 0% | 0 | Common Stock | |
| Xylem Inc | Steven R. Loranger | Director | 18 May 2023 | 1,580 | 13,818 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 2,803 | 55,420 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 898 | 56,318 (0%) | 0% | 0 | Common Stock | |
| Xylem Inc | Steven R. Loranger | Director | 12 May 2022 | 1,812 | 12,238 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 2,300 | 51,880 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 737 | 52,617 (0%) | 0% | 0 | Common Stock | |
| Xylem Inc | Steven R. Loranger | Director | 31 Dec 2021 | 12,491 | 46,407 (0%) | 0% | 0 | Common Stock | ||
| Xylem Inc | Steven R. Loranger | Director | 12 May 2021 | 1,328 | 22,293 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 3,270 | 3,270 | - | - | Director Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 2,615 | 49,580 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 19,797 | 0 | - | - | Director Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Steven R. Loranger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.20 per share. | 16 Nov 2020 | 19,797 | 46,965 (0%) | 0% | 35.2 | 696,789 | Common Stock |
| Xylem Inc | Steven R. Loranger | Director | 11 Sep 2020 | 18,388 | 9,098 (0%) | 0% | 83.9 | 1,543,623 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges